Woodline Partners LP Trims Position in Pfizer Inc. $PFE

Key Points

• Woodline Partners LP reduced its stake in Pfizer Inc. by 8.7% during the 1st quarter, now holding over 1.2 million shares valued at approximately $30.5 million.
• Pfizer recently reported earnings of $0.78 per share for the quarter, surpassing analyst expectations and achieving a revenue of $14.65 billion, a growth of 10.3% year-over-year.
• The company has declared a quarterly dividend of $0.43 per share, yielding 7.0%, with a high dividend payout ratio of approximately 91.49%.

Woodline Partners LP lowered its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 8.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,203,345 shares of the biopharmaceutical company's stock after selling 115,145 shares during the quarter. Woodline Partners LP's holdings in Pfizer were worth $30,493,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Gould Capital LLC boosted its stake in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. bought a new stake in Pfizer during the first quarter worth about $27,000. North Capital Inc. bought a new stake in Pfizer during the first quarter worth about $28,000. Bayforest Capital Ltd bought a new stake in Pfizer during the first quarter worth about $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in Pfizer during the fourth quarter worth about $30,000. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of PFE traded down $0.95 during mid-day trading on Friday, hitting $23.91. 81,158,118 shares of the company traded hands, compared to its average volume of 44,985,973. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The stock has a market cap of $135.94 billion, a price-to-earnings ratio of 12.72, a P/E/G ratio of 0.87 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock has a 50-day moving average price of $24.82 and a two-hundred day moving average price of $24.32.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same period in the prior year, the company earned $0.60 earnings per share. The firm's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's dividend payout ratio is currently 91.49%.

Analyst Ratings Changes

Several research firms recently commented on PFE. Berenberg Bank dropped their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. Morgan Stanley upped their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. Jefferies Financial Group upped their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. Bank of America upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Finally, Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Pfizer currently has an average rating of "Hold" and a consensus price target of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.